Winning payer and provider adoption

# Winning payer and provider adoption

Exact Sciences ran Cologuard through FDA review and CMS coverage review at the same time, under a parallel review pilot, and in 2014 came out with approval and a positive national coverage determination on the same day. A dedicated CPT code followed. Approval, coverage, code: most products never collect all three, and the ones that stall rarely stall on the first.

This lesson deals with the buyer who never meets a rep. A coverage body, an HTA agency, a P&T committee and a tender office each read a different document, on a different clock, with a different test for proof.

The gatekeepers and what each one reads

Payers. Government programs and commercial insurers. They read coverage policy language and a budget-impact model. The question is what happens to next year's spend, and for exactly which patients.

HTA agencies. NICE in England, the G-BA in Germany, HAS in France. They read a full economic evaluation built to a reference case they publish in advance. The question is whether the extra health bought justifies the extra money at national scale.

P&T committees. The Pharmacy and Therapeutics committee inside a hospital or health plan decides what goes on the formulary (the approved list of covered products). It reads a clinical monograph first and the economics second.

Tender authorities. Hospital purchasing groups and national procurement agencies. They read a bid: price, supply guarantees, service terms. Evidence gets you onto the shortlist. The bid decides who wins.

The evidence-based value story your team assembles is raw material for all four, and none of them accepts it in the shape you built it. Each conversion is separate work against a separate template, with its own submission window.

Coding, coverage, and payment

Three words used loosely. They are three separate wins.

Coding is the billing language. A CPT code (Current Procedural Terminology, maintained by the American Medical Association) is the number a provider submits to get paid. New diagnostics often start on an unlisted code, which payers deny by reflex, before earning a specific one.

Coverage is the payer's policy: will we pay, for whom, under what conditions? National (a Medicare NCD) or local (an LCD issued by a regional contractor).

Payment is the dollar amount attached to the code.

You can hold a code and have no coverage. You can hold coverage at a payment rate that loses the provider money every time they use the product, which is an adoption failure that looks from headquarters like clinical resistance and is not.

One instructive gap: a patient with a positive stool-based screening test still needs a colonoscopy, and for years that follow-up was billed as diagnostic rather than preventive, so the patient owed cost-sharing on it. The test was covered; the pathway it triggered was not, and that bill discouraged use of the test. Medicare began phasing the cost-sharing out from 2023. Audit the full patient pathway for holes like this, not just your own line item.

The CMS coverage database is free and public. Reading real NCDs and LCDs teaches you the exact wording payers use to say yes, no, and yes-with-conditions.

HTA appraisal: value at a published price

Where an HTA agency exists, the threshold is written down. NICE appraises against roughly £20,000 to £30,000 per QALY (quality-adjusted life year, a measure combining length and quality of life), with a much higher range reserved for highly specialised technologies. That number is not a negotiating position. It is the arithmetic your submission has to survive, and it means the modelling assumptions (comparator, time horizon, discount rate) matter more than the enthusiasm of your clinical champions.

Biogen's Alzheimer's programme shows how far regulatory and payer verdicts can diverge. Aduhelm held FDA accelerated approval, yet CMS restricted coverage of the anti-amyloid class to patients in approved studies, a coverage-with-evidence-development decision that removed most of the addressable market. Biogen had already cut the annual US price from $56,000 to $28,200 a year earlier; the price cut did not move the coverage question, because the objection was to the strength of the evidence, not the number. In England, NICE later found lecanemab's benefit too small relative to the cost of delivering it on the NHS, despite a UK licence. A regulator can accept your molecule while a payer rejects your file.

Coverage with evidence development, managed access agreements and outcomes-based contracts are the middle answer these bodies reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → for: yes, at this price, if you keep collecting data. Plan for the registry cost before you accept the deal.

The budget-impact model

The per-patient economics prove value. The budget-impact model (BIM) answers the payer's actual fear: what happens to my total spend next year?

Annual budget impact =
  (eligible members × uptake rate × cost per patient of new product)
  minus
  (offsetting costs avoided: hospitalizations, procedures, other drugs)

What gets scrutinised:

• Eligible population. How many covered lives qualify? Payers model the worst case, so an inflated number works against you.
• Uptake rate. Overstating the ramp is the classic own goal. A fast curve tells the payer their exposure arrives immediately.
• Cost offsets. Use a horizon of one to three years. Payers churn members and will not credit savings that land after the patient has left the plan.

Pitching the P&T committee

Coverage logic cleared, the product still needs formulary placement. P&T committees are clinical first. A strong submission carries a tight comparison against the alternatives already on formulary, an explicit place in therapy (first line, or second line after which failure), a proposed tier, and the budget impact run on the committee's own membership numbers.

Propose the prior authorization criteria and step therapy rules yourself rather than waiting to have worse ones imposed. Committees trust a sponsor who names the patients the product is wrong for.

Timing is a real cost here. Most committees meet quarterly and close their packet weeks ahead. Miss the deadline and the launch loses a quarter in a market where the second entrant is already filing.

Tenders: where price does the arguing

In tendered markets the whole apparatus above compresses into a bid. Celltrion built its business on this. Remsima, the first biosimilar monoclonal antibody approved in Europe, entered national procurement with discounts far below the originator's price, and in Norway's tender it took the great majority of the infliximab market inside a year. No amount of value-story craft would have produced that shift; a price did.

Two consequences follow for anyone facing a tender market. Single-winner tenders make you the sole supplier of a hospital system, so a supply interruption becomes a clinical incident and a permanent loss of the account. And the price you accept in one country leaks, through external reference pricing and procurement benchmarking, into every negotiation that follows. Celltrion's later move to bring subcutaneous infliximab to the US as a separately approved biologic rather than a biosimilar is one answer to that trap: change the access route to escape the price anchor.

Aligning the whole motion

Design trials for payers, not only the regulator. A surrogate endpoint may satisfy the FDA and leave a payer unconvinced. If your pivotal study measures only the marker, and against placebo rather than the standard of care, you will spend years arguing about coverage with data that cannot settle the argument.

Engage payers early. Payer advisory boards before launch, and formal early scientific advice in Europe, are cheaper than a second trial.

Fix the billing friction. When a provider says "I would use this but I cannot get paid," that is market access work: coding guides, benefit verification support, appeal letter templates. Marketing owns the fix, and the fix is operational, not persuasive.

When the answer is no

First-submission denials are ordinary. Gather real-world evidence, pursue the coding pathway in parallel, and run a pilot with one health system to generate outcomes on their own patients. Evidence and patience move payers. Volume of promotion does not.

Key Takeaways

• Coverage, coding and payment are three separate wins, and the gaps between them (an uncovered follow-up procedure, a payment rate below provider cost) kill adoption quietly.
• Four institutional readers, four documents: coverage policy for payers, a reference-case economic model for HTA bodies, a clinical monograph for P&T, a priced bid for tenders.
• Where a threshold is published, as at NICE, the modelling assumptions decide the outcome. Biogen's Alzheimer's experience shows a licence and a price cut settle nothing if the evidence is the objection.
• Expect the conditional yes: coverage with evidence development and managed access come with registry costs you must budget before agreeing.
• In tendered markets price does the arguing, and the price you accept in one country follows you into the next.